Pulmonary Arterial Hypertension and HIV Infection

ABSTRACT

Pulmonary arterial hypertension (PAH) is a rare but life-threatening complication of human immunodeficiency virus (HIV) infection. PAH can complicate the course of HIV infection regardless of the route of HIV transmission, the stage of HIV infection, and the degree of immunosuppression. The clinical presentation and underlying pathology of PAH associated with HIV infection (PAH-HIV) are similar to those encountered in other forms of PAH, although there are data suggesting a greater inflammatory component in the HIV-related form. Given the good long-term prognosis of HIV patients with highly active antiretroviral treatments and the severity of PAH in HIV-infected patients, screening for pulmonary hypertension according to a precise algorithm is warranted in HIV-infected patients presenting with dyspnea not explained by another cause. In all cases, right heart catheterization must be performed to establish the diagnosis of PAH. Beneficial effects of antiretroviral treatments on PAH-HIV still remain to be proven. Patients with PAH-HIV appear to respond well to treatment with the prostacyclin epoprostenol, although continuous intravenous infusion is associated with a range of potential complications. Treatment with the oral dual endothelin receptor antagonist bosentan has been shown to benefit patients with PAH-HIV without adversely affecting the control of HIV infection, and resulted in functional and hemodynamic normalization in ~20% of patients. Other PAH therapies, including prostacyclin analogs, type 5 phosphodiesterase inhibitors, and single endothelin receptor antagonists, have yet to be evaluated in PAH-HIV.

Human immunodeficiency virus - pulmonary arterial hypertension - treatment

REFERENCES

• 1 Grubb J R, Moorman A C, Baker R K, Masur H. The changing spectrum of pulmonary disease in patients with HIV infection on antiretroviral therapy.  AIDS. 2006;  20 1095-1107
• 2 Kim K K, Factor S M. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome.  Hum Pathol. 1987;  18 1293-1296
• 3 Opravil M, Pechère M, Speich R et al.. HIV-associated primary pulmonary hypertension: a case control study. Swiss HIV Cohort Study.  Am J Respir Crit Care Med. 1997;  155 990-995
• 4 Humbert M, Sitbon O, Chaouat A et al.. Pulmonary arterial hypertension in France: results from a national registry.  Am J Respir Crit Care Med. 2006;  173 1023-1030
• 5 Nunes H, Humbert M, Sitbon O et al.. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2003;  167 1433-1439
• 6 Petitpretz P, Brenot F, Azarian R et al.. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension.  Circulation. 1994;  89 2722-2727
• 7 Sitbon O, Lascoux-Combe C, Delfraissy J F et al.. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era.  Am J Respir Crit Care Med. 2008;  177 108-113
• 8 Hsue P Y, Deeks S G, Farah H H et al.. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension.  AIDS. 2008;  22 825-833
• 9 Zuber J P, Calmy A, Evison J M Swiss HIV Cohort Study Group et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy.  Clin Infect Dis. 2004;  38 1178-1185
• 10 Opravil M, Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era.  AIDS. 2008;  22(Suppl 3) S35-S40
• 11 Mehta N J, Khan I A, Mehta R N, Sepkowitz D A. HIV-Related pulmonary hypertension: analytic review of 131 cases.  Chest. 2000;  118 1133-1141
• 12 Speich R, Jenni R, Opravil M, Pfab M, Russi E W. Primary pulmonary hypertension in HIV infection.  Chest. 1991;  100 1268-1271
• 13 Pietra G G, Capron F, Stewart S et al.. Pathologic assessment of vasculopathies in pulmonary hypertension.  J Am Coll Cardiol. 2004;  43(12, Suppl S) 25S-32S
• 14 Cool C D, Kennedy D, Voelkel N F, Tuder R M. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection.  Hum Pathol. 1997;  28 434-442
• 15 Sztrymf B, Coulet F, Girerd B et al.. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation.  Am J Respir Crit Care Med. 2008;  177 1377-1383
• 16 Caldwell R L, Gadipatti R, Lane K B, Shepherd V L. HIV-1 TAT represses transcription of the bone morphogenic protein receptor-2 in U937 monocytic cells.  J Leukoc Biol. 2006;  79 192-201
• 17 Humbert M, Monti G, Fartoukh M et al.. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients.  Eur Respir J. 1998;  11 554-559
• 18 Mette S A, Palevsky H I, Pietra G G et al.. Primary pulmonary hypertension in association with human immunodeficiency virus infection: a possible viral etiology for some forms of hypertensive pulmonary arteriopathy.  Am Rev Respir Dis. 1992;  145 1196-1200
• 19 Marecki J C, Cool C D, Parr J E et al.. HIV-1 nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques.  Am J Respir Crit Care Med. 2006;  174 437-445
• 20 Kanmogne G D, Primeaux C, Grammas P. HIV-1 gp120 proteins alter tight junction protein expression and brain endothelial cell permeability: implications for the pathogenesis of HIV-associated dementia.  J Neuropathol Exp Neurol. 2005;  64 498-505
• 21 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension.  N Engl J Med. 2004;  351 1425-1436
• 22 Humbert M. Mediators involved in HIV-related pulmonary arterial hypertension.  AIDS. 2008;  22(Suppl 3) S41-S47
• 23 Rusnati M, Presta M. HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies.  Angiogenesis. 2002;  5 141-151
• 24 Fauci A S, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection.  Ann Intern Med. 1996;  124 654-663
• 25 Morse J H, Barst R J, Itescu S et al.. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles.  Am J Respir Crit Care Med. 1996;  153(4 Pt 1) 1299-1301
• 26 Ascherl G, Hohenadl C, Schatz O et al.. Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy.  Blood. 1999;  93 4232-4241
• 27 Marecki J, Cool C, Voelkel N, Luciw P, Flores S. Evidence for vascular remodeling in the lungs of macaques infected with simian immunodeficiency virus/HIV NEF recombinant virus.  Chest. 2005;  128(6, Suppl) 621S-622S
• 28 Voelkel N F, Cool C D, Flores S. From viral infection to pulmonary arterial hypertension: a role for viral proteins?.  AIDS. 2008;  22(Suppl 3) S49-S53
• 29 Cool C D, Rai P R, Yeager M E et al.. Expression of human herpesvirus 8 in primary pulmonary hypertension.  N Engl J Med. 2003;  349 1113-1122
• 30 Henke-Gendo C, Mengel M, Hoeper M M, Alkharsah K, Schulz T F. Absence of Kaposi's sarcoma-associated herpesvirus in patients with pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2005;  172 1581-1585
• 31 Montani D, Marcelin A G, Sitbon O, Calvez V, Simonneau G, Humbert M. Human herpes virus 8 in HIV and non-HIV infected patients with pulmonary arterial hypertension in France.  AIDS. 2005;  19 1239-1240
• 32 Pugliese A, Isnardi D, Saini A, Scarabelli T, Raddino R, Torre D. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement.  J Infect. 2000;  40 282-284
• 33 Petrache I, Diab K, Knox K S et al.. HIV associated pulmonary emphysema: a review of the literature and inquiry into its mechanism.  Thorax. 2008;  63 463-469
• 34 Thabut G, Dauriat G, Stern J B et al.. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation.  Chest. 2005;  127 1531-1536
• 35 McGoon M, Gutterman D, Steen V American College of Chest Physicians et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.  Chest. 2004;  126(1, Suppl) 14S-34S
• 36 Degano B, Yaici A, Le Pavec J et al.. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension.  Eur Respir J. 2009;  33 92-98
• 37 Lebrec D. Methods to evaluate portal hypertension.  Gastroenterol Clin North Am. 1992;  21 41-59
• 38 Lijfering W M, Ten Kate M K, Sprenger H G, van der Meer J. Absolute risk of venous and arterial thrombosis in HIV-infected patients and effects of combination antiretroviral therapy.  J Thromb Haemost. 2006;  4 1928-1930
• 39 Heron E, Laaban J P, Capron F, Quieffin J, Brechot J M, Rochemaure J. Thrombotic primary pulmonary hypertension in an HIV+ patient.  Eur Heart J. 1994;  15 394-396
• 40 Escamilla R, Hermant C, Berjaud J, Mazerolles C, Daussy X. Pulmonary veno-occlusive disease in a HIV-infected intravenous drug abuser.  Eur Respir J. 1995;  8 1982-1984
• 41 Montani D, Achouh L, Dorfmüller P et al.. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.  Medicine (Baltimore). 2008;  87 220-233
• 42 Galiè N, Torbicki A, Barst R et al.. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.  Eur Heart J. 2004;  25 2243-2278
• 43 Badesch D B, Abman S H, Simonneau G, Rubin L J, McLaughlin V V. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines.  Chest. 2007;  131 1917-1928
• 44 Hebert V Y, Crenshaw B L, Romanoff R L, Ekshyyan V P, Dugas T R. Effects of HIV drug combinations on endothelin-1 and vascular cell proliferation.  Cardiovasc Toxicol. 2004;  4 117-131
• 45 Jiang B, Hebert V Y, Zavecz J H, Dugas T R. Antiretrovirals induce direct endothelial dysfunction in vivo.  J Acquir Immune Defic Syndr. 2006;  42 391-395
• 46 Pellicelli A M, Palmieri F, D'Ambrosio C et al.. Role of human immunodeficiency virus in primary pulmonary hypertension: case reports.  Angiology. 1998;  49 1005-1011
• 47 Barbaro G, Lucchini A, Pellicelli A M, Grisorio B, Giancaspro G, Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension.  Heart. 2006;  92 1164-1166
• 48 Speich R, Jenni R, Opravil M, Jaccard R. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy.  Swiss Med Wkly. 2001;  131 663-665
• 49 Bonora S, Lanzafame M, D'Avolio A et al.. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment.  Clin Infect Dis. 2008;  46 146-147
• 50 Sitbon O, Humbert M, Jaïs X et al.. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.  Circulation. 2005;  111 3105-3111
• 51 Glesby M J, Aberg J A, Kendall M A Adult AIDS Clinical Trials Group A5159 Protocol Team et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.  Clin Pharmacol Ther. 2005;  78 143-153
• 52 Aguilar R V, Farber H W. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension.  Am J Respir Crit Care Med. 2000;  162 1846-1850
• 53 Limsukon A, Saeed A I, Ramasamy V, Nalamati J, Dhuper S. HIV-related pulmonary hypertension.  Mt Sinai J Med. 2006;  73 1037-1044
• 54 Stricker H, Domenighetti G, Mombelli G. Prostacyclin for HIV-associated pulmonary hypertension.  Ann Intern Med. 1997;  127 1043
• 55 Ghofrani H A, Friese G, Discher T et al.. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension.  Eur Respir J. 2004;  23 321-326
• 56 Cea-Calvo L, Escribano Subías P, Tello de Menesses R et al.. Treatment of HIV-associated pulmonary hypertension with treprostinil [in Spanish].  Rev Esp Cardiol. 2003;  56 421-425
• 57 Alp S, Schlottmann R, Bauer T T, Schmidt W E, Bastian A. Long-time survival with HIV-related pulmonary arterial hypertension: a case report.  AIDS. 2003;  17 1714-1715
• 58 Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension.  AIDS. 2002;  16 1568-1569
• 59 Schumacher Y O, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension.  AIDS. 2001;  15 1747-1748
• 60 Merry C, Barry M G, Ryan M et al.. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.  AIDS. 1999;  13 F101-F107
• 61 Muirhead G J, Wulff M B, Fielding A, Kleinermans D, Buss N. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.  Br J Clin Pharmacol. 2000;  50 99-107
• 62 Sildenafil Summary of Product Characteristics. Available at: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=17443#CONTRAINDICATIONS
• 63 Sitbon O, Gressin V, Speich R et al.. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.  Am J Respir Crit Care Med. 2004;  170 1212-1217
• 64 Humbert M, Segal E S, Kiely D G, Carlsen J, Schwierin B, Hoeper M M. Results of European post-marketing surveillance of bosentan in pulmonary hypertension.  Eur Respir J. 2007;  30 338-344